Liang Dai

机构：China Pharmaceutical University, City University of Hong Kong · ORCID：0000-0003-0172-4759

发表论文 73 篇 · 总被引 1530 次 · h-index 23

代表论文

• METTL3 promotes colorectal carcinoma progression by regulating the m6A–CRB3–Hippo axis (2022 · Journal of Experimental & Clinical Cancer Research · 被引 105)
• Discovery of Orally Bioavailable N -Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer (2022 · Journal of Medicinal Chemistry · 被引 32)
• Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis (2022 · Journal of Medicinal Chemistry · 被引 30)
• Discovery of an Orally Bioavailable STING Inhibitor with In Vivo Anti-Inflammatory Activity in Mice with STING-Mediated Inflammation (2025 · Journal of Medicinal Chemistry · 被引 24)
• Achieving deep intratumoral penetration and multimodal combined therapy for tumor through algal photosynthesis (2024 · Journal of Nanobiotechnology · 被引 17)
• Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases (2023 · Journal of Medicinal Chemistry · 被引 17)